FluoroPharma Announces CardioPET Phase II Results at the 21st American Society of Nuclear Cardiology (ASNC) Meeting

MONTCLAIR, NJ–(Marketwired – September 26, 2016) – FluoroPharma Medical Inc. (OTCQB: FPMI) announced today that data from its Phase II clinical trial for CardioPET were presented at the 21^st Annual Meeting of the American Society of Nuclear Cardiology on September 24^th, 2016 in Boca Raton, Florida.

Source: http://www.marketwired.com/mw/release.do?id=2161421&sourceType=3